Published finding — does the expert body still believe it?
Evolocumab treatment in ASCVD patients on statins was not associated with a significant increase in new-onset diabetes or neurocognitive adverse events compared with placebo.
TL;DR · AI-generated
In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
Author-implied confidence
82%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
92% → 92% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
· openalex W2596179513 · s2 993698dd
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1710
Evolocumab significantly reduced the key secondary composite endpoint of cardiovascular death, MI, or stroke (HR 0.80; 95% CI 0.73–0.88) compared with placebo in ASCVD patients receiving background statin therapy.
0.1835
Evolocumab added to statin therapy significantly reduced the composite primary endpoint of cardiovascular death, MI, stroke, unstable angina hospitalization, or coronary revascularization (HR 0.85; 95% CI 0.79–0.92) in ASCVD patients over a median 2.2-year follow-up.
0.2065
In patients with atherosclerotic cardiovascular disease on statin therapy, evolocumab reduced LDL cholesterol by 59% at 48 weeks, from a median of 92 mg/dL to 30 mg/dL, compared with placebo.
0.2103
Alirocumab treatment is associated with a numerically lower all-cause mortality rate compared to placebo in post-ACS patients on high-intensity statins (3.5% vs. 4.1%; HR 0.85; 95% CI 0.73–0.98).
0.2108
The cardiovascular benefit of evolocumab will be shown to persist or increase with longer follow-up beyond the 2.2-year median observed in the FOURIER trial.
0.2151
The absolute cardiovascular benefit of alirocumab over placebo is greater in post-ACS patients with a baseline LDL cholesterol of 100 mg/dL or higher compared to those with lower baseline LDL levels.